Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
NextCure, Inc.
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05572684CT.gov A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| NC 410 (this asset) | NextCure, Inc. | P1/2 | CC · 47 |
| Nepenthe | Instituto Nacional de Cancer, Brazil | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P3 | BB |
| Lidocaine | Instituto Nacional de Cancer, Brazil | P3 | BB |
| Carboplatin | Rapa Therapeutics LLC | P3 | BB |
| Cetuximab | Pfizer | P3 | BB |
| Cyclophosphamide | Zelluna Immunotherapy AS | P3 | BB |
| Nivestim | University of Colorado, Denver | P2 | BB |
| Pembrolizumab | Thomas Jefferson University | P3 | BB |
+41 more in the Head And Neck Cancer cohort
Other indications for NC 410
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P1/2 | CC · 46 |
| Pancreatic Neoplasm | — | P2 | CC · 44 |
| Gastric Cancer | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. NC 410 in Head And Neck Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nc-410-head-and-neck-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →